September 18th 2023
Thomas G. Martin, MD, discussed with his colleagues cytokine release syndrome after treatment with teclistamab for patients with multiple myeloma.
September 11th 2023
Advances In™: Meeting Unmet Clinical Needs in AML with Evolving Therapeutic Approaches
View More
Bridging the Care Gap in Anemia in CKD: A Comprehensive Guide to Enhancing Patient Care
Register Now!
Antibody-Drug Conjugates in Gynecological Cancer – Setting the Stage
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
4th Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis
View More
Burst CME: Regulatory Approval Pathways for Influenza Vaccines
View More
Medical Crossfire®: Experts Address Your Burning Questions on the Evolving Treatment of MF, PV, and ET!
View More
Oncology Consultations®: Leveraging Clinical Data and Trials to Inform Treatment for Patients with PV
View More
Clinical Interchange™: Improving Outcomes and Overcoming Barriers to Equitable Care in African American Patients With Multiple Myeloma
View More
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow
View More
Updates from the Annual Hematology Meeting: Matching the Tumor with Patient Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of CLL
View More
Follicular Lymphoma Workshop: Forging Patient-Centric Plans with Targeted Therapies Across Lines of Care
View More
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in the Treatment of MPNs
View More
Medical Crossfire®: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult
View More
Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GVHD?
View More
"D" is for Diagnosis: Deciphering Uncommon Hematologic Disorders Through the Eyes of a Detective
View More
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
View More
Community Practice Connections™: How We Do It: Application of State-of-the-Art MF and PV Care Today… With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Oncology Roundtable: Treating MF and PV in 2023
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Keeping Pace with Rapid Advancements in Multiple Myeloma Care
View More
Community Practice Connections™: Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings
View More
Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in GvHD Prevention and Treatment
View More
Community Practice Connections™: MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
View More
Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical Progression
In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
Biochemical vs Clinical Progression in Relapsed/Refractory Multiple Myeloma
Expert Wilson Gonsalves, MD, shares clinical data in multiple myeloma centered on the distinction between biochemical versus clinical progression.
Relapsed/Refractory Multiple Myeloma: The IKEMA Study
Covering the first of two abstracts, Wilson Gonsalves, MD, reviews data from the IKEMA study of isatuximab KD in patients with relapsed/refractory multiple myeloma.
Cross Q&A: Isatuximab + Pom-Dex in Relapsed/Refractory Multiple Myeloma
Panelists from both the Mayo Clinic and UT Southwestern comment on data from ALLIANCE A061202 and consider the role of isatuximab in patients with relapsed/refractory multiple myeloma.
Relapsed/Refractory Multiple Myeloma: The ALLIANCE A061202 Study
Adeel Khan, MD, MPH, MS, expert in multiple myeloma management, reviews data from the ALLIANCE A061202 trial of isatuximab + pomalidomide + dexamethasone in relapsed/refractory disease.
Cross Q&A: Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Experts from the Mayo Clinic and UT Southwestern share insight on the CARTITUDE-4 study and ciltacabtagene autoleucel in the second cross Q&A session.
Relapsed/Refractory Multiple Myeloma: The CARTITUDE-4 Study
Key opinion leader Prashant Kapoor, MD, FACP, shares data from the CARTITUDE-4 study of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.
Cross Q&A: Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma
Panelists follow up with questions and comments on the KarMMa-3 study in relapsed/refractory multiple myeloma and consider how idecabtagene vicleucel might fit into real-world practice.